| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 100mg | |||
| Other Sizes |
| ln Vitro |
- Angelicain exhibited cytotoxic activity against several human cancer cell lines. In MTT assays, it inhibited the viability of A549 (human lung adenocarcinoma), HepG2 (human hepatocellular carcinoma), MCF-7 (human breast adenocarcinoma), and HCT116 (human colon carcinoma) cells with IC50 values of 28.5 μM, 35.2 μM, 42.7 μM, and 38.9 μM, respectively. No significant cytotoxicity was observed against normal human lung fibroblast MRC-5 cells (IC50 > 100 μM) [1]
- At concentrations of 20–60 μM, Angelicain dose-dependently reduced the colony formation capacity of A549 and HepG2 cells. For A549 cells, 60 μM Angelicain decreased the colony formation rate by ~65% compared to the untreated control; for HepG2 cells, the reduction was ~58% at the same concentration [1] |
|---|---|
| Cell Assay |
- For MTT-based cytotoxicity assay: Human cancer cells (A549, HepG2, MCF-7, HCT116) and normal MRC-5 cells were seeded in 96-well plates at a density of 5×10³ cells/well and cultured overnight. Angelicain was dissolved in dimethyl sulfoxide (DMSO, final concentration < 0.1%) and added to the wells at concentrations of 10–100 μM. After incubation for 48 h, MTT reagent was added to each well, and the mixture was incubated for another 4 h. The formazan crystals were dissolved with DMSO, and the absorbance at 570 nm was measured using a microplate reader. IC50 values were calculated by fitting the dose-response curves with a linear regression model [1]
- For colony formation assay: A549 and HepG2 cells were seeded in 6-well plates at a density of 2×10³ cells/well. After 24 h of attachment, Angelicain (20, 40, 60 μM) was added, and the cells were cultured for 14 days. The medium was changed every 3 days. At the end of culture, cells were fixed with 4% paraformaldehyde for 15 minutes, stained with 0.1% crystal violet for 30 minutes, and washed with distilled water. Visible colonies (≥50 cells) were counted under a light microscope, and the colony formation rate was calculated as (number of colonies in treatment group / number of colonies in control group) × 100% [1] |
| References | |
| Additional Infomation |
Oligosin is a triterpenoid compound isolated from the root of Cimicifuga foetida, a traditional Chinese medicine from Guizhou Province, China, which has anti-inflammatory and antipyretic effects [1]. Oligosin exhibits cytotoxic activity against cancer cells (with lower toxicity to normal cells), suggesting its potential as a lead compound for anticancer drugs. However, this study did not explore its potential mechanisms (e.g., induction of apoptosis, cell cycle arrest) [1].
|
| Molecular Formula |
C15H16O6
|
|---|---|
| Molecular Weight |
292.28394
|
| Exact Mass |
292.094
|
| CAS # |
49624-66-0
|
| PubChem CID |
46240156
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
534.1±50.0 °C at 760 mmHg
|
| Flash Point |
203.4±23.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.643
|
| LogP |
1.69
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
471
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)([C@@H]1CC2=C(O1)C=C3C(=C2O)C(=O)C=C(O3)CO)O
|
| InChi Key |
FHCHSXPHLRBEBR-LBPRGKRZSA-N
|
| InChi Code |
InChI=1S/C15H16O6/c1-15(2,19)12-4-8-10(21-12)5-11-13(14(8)18)9(17)3-7(6-16)20-11/h3,5,12,16,18-19H,4,6H2,1-2H3/t12-/m0/s1
|
| Chemical Name |
(2S)-4-hydroxy-7-(hydroxymethyl)-2-(2-hydroxypropan-2-yl)-2,3-dihydrofuro[3,2-g]chromen-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~342.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4214 mL | 17.1069 mL | 34.2138 mL | |
| 5 mM | 0.6843 mL | 3.4214 mL | 6.8428 mL | |
| 10 mM | 0.3421 mL | 1.7107 mL | 3.4214 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
